dc.contributor.author | Sargsyan, A | |
dc.contributor.author | Kucharczyk, MA | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Constantinidou, A | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-04-19T10:29:35Z | |
dc.date.available | 2023-04-19T10:29:35Z | |
dc.date.issued | 2023-02-01 | |
dc.identifier.citation | Expert Review of Gastroenterology and Hepatology, 2023, 17 (2), pp. 119 - 127 | en_US |
dc.identifier.issn | 1747-4124 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5756 | |
dc.identifier.eissn | 1747-4132 | |
dc.identifier.eissn | 1747-4132 | |
dc.identifier.doi | 10.1080/17474124.2023.2167711 | |
dc.description.abstract | INTRODUCTION: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate revolutionized the management of advanced/metastatic GIST, and remains the standard first-line therapy in this setting. Upon development of secondary resistance, sunitinib and regorafenib are used as subsequent treatments, although clinical benefit is often non-durable. Ripretinib is a type II kinase inhibitor targeting KIT and PDGFRA mutations and resistance through switching active I and inactive II forms. AREAS COVERED: This drug profile article provides an overview of the current state of the art treatment algorithm for advanced/metastatic GIST, focusing on the role of ripretinib in the fourth-line setting as defined by currently available clinical trials evidence. The mechanism of action, the safety profile, efficacy, and clinical application of ripretinib are presented. In addition, the Phase I study (NCT02571036) through which the optimal dose was established and the Phase III trials that assessed the efficacy and safety of ripretinib as fourth- (INVICTUS) and second-line treatment (INTRIGUE) are presented. EXPERT OPINION: Ripretinib is a safe and an effective therapy for the fourth-line setting in advanced/metastatic GIST. Future studies should evaluate combination schedules and the identification of markers predictive of benefit from ripretinib. | |
dc.format | Print-Electronic | |
dc.format.extent | 119 - 127 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | TAYLOR & FRANCIS LTD | en_US |
dc.relation.ispartof | Expert Review of Gastroenterology and Hepatology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Gastrointestinal stromal tumor | |
dc.subject | KIT | |
dc.subject | kinase inhibitor | |
dc.subject | mutations | |
dc.subject | resistance | |
dc.subject | ripretinib | |
dc.subject | systemic treatment | |
dc.subject | Adult | |
dc.subject | Humans | |
dc.subject | Antineoplastic Agents | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Gastrointestinal Neoplasms | |
dc.subject | Gastrointestinal Stromal Tumors | |
dc.subject | Imatinib Mesylate | |
dc.subject | Mutation | |
dc.subject | Protein Kinase Inhibitors | |
dc.title | Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-01-09 | |
dc.date.updated | 2023-04-19T10:28:40Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1080/17474124.2023.2167711 | en_US |
rioxxterms.licenseref.startdate | 2023-02-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36644853 | |
pubs.issue | 2 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1080/17474124.2023.2167711 | |
pubs.volume | 17 | |
dc.contributor.icrauthor | Jones, Robin | |
icr.provenance | Deposited by Mr Arek Surman on 2023-04-19. Deposit type is initial. No. of files: 1. Files: Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.pdf | |